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Background: Prior studies have focused on the clinical efficacy of combination 
therapy, Donepezil and Memantine, for patient’s diagnosed with Alzheimer’s disease. 
However, the potential adverse drug reactions while described as mild can have 
serious sequelae in older adults who are already managing the side effects of 
polypharmacy. 
Objective: This study looks to explore the tolerability of switching cholinesterase 
inhibitors to memantine monotherapy versus adding memantine as combination 
therapy for all-cause neurodegenerative disorders. 
Methods: The study is a retrospective chart review that includes 175 patients aged 50 
and older diagnosed with neurocognitive disorders (ICD 10 F00-F03.91 and ICD10 
G30-G31.84) managed on combination therapy, memantine monotherapy and CI 
monotherapy from 2016-2019. 
Results: The odds of a patient reporting side effects on combination therapy in 
comparison with those patients on memantine monotherapy reporting side effects 
were significantly greater (OR = 4.33, CI 95% (1.62, 11.52), p=0.003). There was 
marginal significance in variables such as polypharmacy (p=0.057) and dosing of 
cholinesterase inhibitors (p = 0.087) in a binary logistic regression model (Table 1). Of 
the patient population who qualified as excessive polypharmacy (>10), more than half 
60% reported side effects.
Discussion: The likelihood of reporting side effects is significantly increased for 
patients on combination therapy when compared to those on monotherapy(p=0.003). 
Sample size was a limiting factor in determining significant predictors for those 
reporting side effects on combination therapy; however, there was marginal 
significance for patients on > 4 other medications while on combination therapy 
(p=0.057) in predicting outcomes. In our patient sample, more than 80% of the 
patients reporting side effects qualified as polypharmacy or excessive polypharmacy. 
Variables such as severity of disease (p=0.148) and memantine (p=0.868) were not significant 
predictors for those reporting side effects on combination therapy, however, there was 
marginal significance in variables such as polypharmacy (p=0.057) and dosing of 
cholinesterase inhibitors (p = 0.087) in a binary logistic regression model (Table 1). Of the 
patient population who qualified as excessive polypharmacy (>10), more than half 60% 
reported side effects (Table 1).
Combination Therapy* Memantine Monotherapy  
  N %   N % 
No Side 
Effect 
43 32% No Side Effect 35 26% 
Side Effect 31 78% Side Effect 6 14% 
 
• The odds of a patient reporting side effects on combination therapy in comparison with 
those patients on memantine monotherapy reporting side effects are significantly greater 
(p=0.003). 
• Polypharmacy has previously been described as four or more medications and the 
potential for negative outcomes (adverse drug events, non-adherence or drug interactions) 
in older people.  
• Sample size was a limiting factor in determining significant predictors for those reporting 
side effects on combination therapy; however, there was marginal significance for patients 
on > 4 other medications while on combination therapy (p=0.057) in predicting outcomes.
• In our patient sample, more than 80% of the patients reporting side effects qualified as 
polypharmacy or excessive polypharmacy.  
• The rates of non-adherence around the world exceed 50% among the poly-medicated 
elderly with 50% of dropouts occurring in the first six months of treatment.  
• Overall, this is a patient population that eventually succumbs to terminal-stage 
complications that relate to advanced debilitation, such as dehydration, malnutrition and 
infection. 
• An objective for clinicians is to obtain a balance between aggressively treating diseases 
while avoiding medication related harm. 
• Consider switching CI monotherapy to memantine monotherapy when managing patients 
with mild to moderate disease to increase the likelihood of tolerability. Consider the 
number of other medications the patient is taking and the severity of the patient’s 
cognitive impairment to determine if the clinical benefit will outweigh the risk. 
• Further research is needed to explore the efficacy in all-cause neurodegenerative 
disorders. 
• Limitations: As a retrospective chart review causation cannot be determined, only 
association. Furthermore, the sample size was a limiting factor in determining more 
reliable predictors for those reporting side effects.
The more frequently reported side effects in the combination therapy group were sleep 
impairment, dizziness, and diarrhea, respectively (Figure 2). 
A majority of the patients 83.9% were on high dose memantine therapy and 12.9% were 









6 6 6 9
p=0.057 50% 50% p = 0.087 40% 60%
31 16 Medium 25 18
66% 34% 58% 42%
6 9 High 12 4
40% 60% 75% 25%
43 31 Total 43 31









Mild 12 15 Low 0 0
p=0.148 44% 56% p=0.868 0% 0%
Moderate 20 2 Medium 8 5
91% 9% 62% 38%
Severe 7 12 High 35 26
37% 63% 57% 43%
unknown 4 2 Total 43 31
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The odds of a patient reporting side effects on combination therapy in comparison 
with those patients on memantine monotherapy reporting side effects were 
significantly greater (OR = 4.33, CI 95% (1.62, 11.52), p=0.003). (Table 2).  
All-cause neurodegenerative disorders were included in this study with a majority of patients 
diagnosed with AD in all 3 treatment groups (Figure 1). Followed by Mixed AD/VD in the 
combination therapy group, FTD in the memantine monotherapy group and MCI in the CI 
monotherapy group. The more frequently reported side effects in the combination therapy 
group were sleep impairment, dizziness, and diarrhea, respectively (Figure 2). 
Table 1. Combination Therapy- Dosing Other Medications and Severity
Figure 1. Neurodegenerative Disorders
Figure 2. Side Effects Reported
Table 2. Side Effects
